Body mass and composition affect bone density in recently diagnosed inflammatory bowel disease: The Manitoba IBD cohort study

Authors

  • William D. Leslie MD, MSc,

    Corresponding author
    1. Department of Medicine, University of Manitoba, Winnipeg, MB, Canada
    2. Inflammatory Bowel Disease Research Centre, University of Manitoba, Winnipeg, MB, Canada
    • Department of Medicine (C5121), 409 Tache Ave., Winnipeg, Canada R2H 2A6
    Search for more papers by this author
    • William Leslie has received speaker fees, research honoraria, and unrestricted research grants from Merck Frosst Canada Ltd; research honoraria and unrestricted educational grants from Sanofi-Aventis, Procter & Gamble Pharmaceuticals Canada, Inc. and Novartis Pharmaceuticals Canada, Inc.

  • Norine Miller RN,

    1. Department of Medicine, University of Manitoba, Winnipeg, MB, Canada
    2. Inflammatory Bowel Disease Research Centre, University of Manitoba, Winnipeg, MB, Canada
    Search for more papers by this author
  • Linda Rogala RN,

    1. Department of Medicine, University of Manitoba, Winnipeg, MB, Canada
    2. Inflammatory Bowel Disease Research Centre, University of Manitoba, Winnipeg, MB, Canada
    Search for more papers by this author
  • Charles N. Bernstein MD

    1. Department of Medicine, University of Manitoba, Winnipeg, MB, Canada
    2. Inflammatory Bowel Disease Research Centre, University of Manitoba, Winnipeg, MB, Canada
    Search for more papers by this author
    • Charles Bernstein has received consultant fees from Abbott Pharmaceuticals, Astra Zeneca Canada, Axcan Pharma, Schering AG, Shire Pharmaceuticals Canada, UCB Canada.


Abstract

Background: This prospective study was undertaken to clarify the role of body mass and composition as a determinant of bone mineral density (BMD) in recently diagnosed inflammatory bowel disease (IBD).

Methods: A nested subgroup of 101 adult subjects of the population-based Manitoba IBD Cohort Study were enrolled. Baseline BMD and body composition were measured and repeated 2.3 ± 0.3 years later.

Results: Greater weight, height, and body mass measurements were positively correlated with bone density at all sites (P < 0.01). Although both fat tissue and lean tissue showed positive relationships with BMD, lean tissue showed a much stronger correlation than fat tissue, especially for the total hip (r = 0.66, P < 0.001 versus r = 0.23, P < 0.05) and total body measurements (r = 0.59, P < 0.001 versus r = 0.04, P NS). Increase (or decrease) in hip bone density was strongly associated with an increase (or decrease) in all body mass variables (r = 0.49–0.54, P < 0.001).

Conclusions: Measures of body mass are important determinants of baseline BMD in recently diagnosed IBD patients. Furthermore, change in body mass is correlated with change in BMD, especially at the total hip. Early optimization and maintenance of nutrition and body weight, particularly toward lean tissue mass, may play an important role in preventing IBD-related bone disease.

(Inflamm Bowel Dis 2008)

Ancillary